These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R mBio; 2017 Sep; 8(5):. PubMed ID: 28928215 [TBL] [Abstract][Full Text] [Related]
3. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus. Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951 [TBL] [Abstract][Full Text] [Related]
4. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses. Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P J Virol; 2017 May; 91(9):. PubMed ID: 28179535 [TBL] [Abstract][Full Text] [Related]
5. Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies. Roos A; Roozendaal R; Theeuwsen J; Riahi S; Vaneman J; Tolboom J; Dekking L; Koudstaal W; Goudsmit J; Radošević K Vaccine; 2015 Mar; 33(14):1739-47. PubMed ID: 25659276 [TBL] [Abstract][Full Text] [Related]
6. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines. Jang YH; Jung EJ; Byun YH; Lee KH; Lee EY; Lee YJ; Seong BL Vaccine; 2013 Jul; 31(33):3339-46. PubMed ID: 23742997 [TBL] [Abstract][Full Text] [Related]
8. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza. Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565 [TBL] [Abstract][Full Text] [Related]
9. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge. Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689 [TBL] [Abstract][Full Text] [Related]
10. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies. Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855 [TBL] [Abstract][Full Text] [Related]
11. T-cell-mediated cross-strain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccine. Li J; Arévalo MT; Chen Y; Chen S; Zeng M Int J Infect Dis; 2014 Oct; 27():37-43. PubMed ID: 25172265 [TBL] [Abstract][Full Text] [Related]
12. A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus. Chang H; Huang C; Wu J; Fang F; Zhang W; Wang F; Chen Z Virol J; 2010 Aug; 7():197. PubMed ID: 20727202 [TBL] [Abstract][Full Text] [Related]
13. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. Nachbagauer R; Wohlbold TJ; Hirsh A; Hai R; Sjursen H; Palese P; Cox RJ; Krammer F J Virol; 2014 Nov; 88(22):13260-8. PubMed ID: 25210189 [TBL] [Abstract][Full Text] [Related]
14. Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene. Kamlangdee A; Kingstad-Bakke B; Anderson TK; Goldberg TL; Osorio JE J Virol; 2014 Nov; 88(22):13300-9. PubMed ID: 25210173 [TBL] [Abstract][Full Text] [Related]
16. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice. Lei H; Peng X; Jiao H; Zhao D; Ouyang J Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406 [TBL] [Abstract][Full Text] [Related]
17. Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach. Sun W; Kirkpatrick E; Ermler M; Nachbagauer R; Broecker F; Krammer F; Palese P J Virol; 2019 Jun; 93(12):. PubMed ID: 30944178 [TBL] [Abstract][Full Text] [Related]